XML Sitemap

This is a XML Sitemap which is supposed to be processed by search engines which follow the XML Sitemap standard like Ask.com, Bing, Google and Yahoo.
It was generated using the WordPress content management system and the Google Sitemap Generator Plugin by Arne Brachhold.
You can find more information about XML sitemaps on sitemaps.org and Google's list of sitemap programs.

URLPriorityChange frequencyLast modified (GMT)
https://realendpoints.com/mk-news/outcomes-claim-may-help-amgen-make-case-for-pcsk9-inhibitor-repatha/60%Monthly2018-02-05 21:26
https://realendpoints.com/mk-news/families-fret-as-insurers-mull-biogens-750k-spine-disease-drug/60%Monthly2018-01-17 19:39
https://realendpoints.com/mk-news/drugmakers-are-trying-a-new-strategy-charging-less/60%Monthly2018-01-17 18:12
https://realendpoints.com/mk-news/guest-commentary-the-tipping-point/60%Monthly2018-01-21 18:31
https://realendpoints.com/mk-news/the-shrinking-value-of-best-in-class-and-first-in-class-drugs/60%Monthly2017-12-21 12:04
https://realendpoints.com/mk-news/guest-commentary-overvaluing-speed-to-market/60%Monthly2018-01-21 18:31
https://realendpoints.com/mk-news/overcoming-the-political-and-economic-roadblocks-stopping-effective-comparative-drug-evaluation/60%Monthly2018-01-21 18:43
https://realendpoints.com/mk-news/who-has-the-power-to-cut-drug-prices-employers/60%Monthly2018-01-21 18:29
https://realendpoints.com/mk-news/the-myth-of-the-payer/60%Monthly2018-01-21 18:30
https://realendpoints.com/mk-news/who-has-the-power-to-cut-drug-prices/60%Monthly2018-01-21 18:28
https://realendpoints.com/mk-news/smart-segmentation-success-in-the-payer-dominated-pharma-marketplace/60%Monthly2018-01-31 20:41
https://realendpoints.com/mk-news/roger-longman-on-the-drug-pricing-war/60%Monthly2018-01-22 20:37
https://realendpoints.com/mk-news/contracting-2-0-the-why-when-how-and-why-not-of-value-based-deals/60%Monthly2018-01-21 18:26
https://realendpoints.com/mk-news/the-value-lab-moving-value-based-health-care-from-theory-to-practice/60%Monthly2018-02-06 18:37
https://realendpoints.com/mk-news/buyside-view-xxiii-milestones-galore/60%Monthly2018-01-17 21:23
https://realendpoints.com/mk-news/pharma-needs-to-get-into-digitial-health-data-game-to-stay-competitive-study-says/60%Monthly2018-01-17 21:14
https://realendpoints.com/mk-news/partitioning-hcv/60%Monthly2018-01-17 21:22
https://realendpoints.com/mk-news/prepping-for-pcsk9s/60%Monthly2018-01-21 19:55
https://realendpoints.com/mk-news/games-up-pharma-the-new-drug-pricing-dynamics/60%Monthly2018-01-17 21:20
https://realendpoints.com/mk-news/drugabacus-pricing-tool-helps-payers-calculate-fair-value-of-cancer-drugs/60%Monthly2018-02-05 21:12
https://realendpoints.com/mk-news/the-specialty-drug-price-debate-should-medtech-be-worried/60%Monthly2018-01-17 21:17
https://realendpoints.com/mk-news/21st-century-pharmaceutical-collaboration-the-value-convergence/60%Monthly2018-01-17 21:15
https://realendpoints.com/mk-news/paying-in-heart-failure/60%Monthly2018-01-21 19:56
https://realendpoints.com/mk-news/gilead-plays-hardball-with-hep-c-patient-assistance/60%Monthly2018-01-17 21:13
https://realendpoints.com/mk-news/shifting-ms-spending/60%Monthly2018-01-17 21:09
https://realendpoints.com/mk-news/scoring-value-new-tools-challenge-pharmas-us-pricing-bonanza/60%Monthly2018-01-17 21:08
https://realendpoints.com/mk-news/drugmakers-explore-response-to-pricing-debate/60%Monthly2018-01-17 21:07
https://realendpoints.com/mk-news/competition-alone-wont-cut-it-on-drug-prices/60%Monthly2018-01-17 21:07
https://realendpoints.com/mk-news/roche-reviewing-next-steps-for-lebrikizumab-after-mixed-phase-iii-data/60%Monthly2018-02-05 21:14
https://realendpoints.com/mk-news/pharmacy-benefit-melee-anthem-vs-epress-scripts-suit-hinges-on-benchmark-pricing/60%Monthly2018-02-05 21:15
https://realendpoints.com/mk-news/the-dream-team-that-could-fix-drug-pricing-part-2/60%Monthly2018-01-17 21:01
https://realendpoints.com/mk-news/payers-sued-over-coverage-of-expensive-hepatitis-c-drugs/60%Monthly2018-01-17 21:00
https://realendpoints.com/mk-news/how-can-migraine-drugmakers-avoid-the-pcsk9-debacle/60%Monthly2018-01-17 21:00
https://realendpoints.com/mk-news/pcsk9-sponsors-payers-in-the-ring-at-acc/60%Monthly2018-01-17 20:56
https://realendpoints.com/mk-news/the-blues-singer-who-created-americas-hated-drug-pricing-model/60%Monthly2018-01-17 19:56
https://realendpoints.com/mk-news/key-us-entresto-barriers-are-pa-process-co-payments-bmt-poll/60%Monthly2018-02-05 21:19
https://realendpoints.com/mk-news/is-the-biotech-boom-slowing-down/60%Monthly2018-01-17 19:54
https://realendpoints.com/mk-news/bundled-contracts-to-defend-against-biosimilars-may-face-payer-skepticism/60%Monthly2018-02-05 21:16
https://realendpoints.com/mk-news/paving-the-way/60%Monthly2018-01-17 19:47
https://realendpoints.com/mk-news/gilead-sees-prospects-for-declining-hcv-revenues-to-stabilize/60%Monthly2018-02-05 21:19
https://realendpoints.com/mk-news/will-real-world-data-sway-course-of-novel-anticoagulant-market/60%Monthly2018-02-05 21:20
https://realendpoints.com/mk-news/indication-based-pricing-could-be-windfall-for-interleukin-inhibitors/60%Monthly2018-02-05 21:21
https://realendpoints.com/mk-news/getting-ahead-of-headache/60%Monthly2018-01-21 19:55
https://realendpoints.com/mk-news/as-drug-value-frameworks-gain-traction-patients-seek-more-input/60%Monthly2018-02-05 21:16
https://realendpoints.com/mk-news/long-acting-pcsk9-from-alnylam-tmc-heads-for-phiii-but-safety-spooks-investors/60%Monthly2018-01-17 21:56
https://realendpoints.com/mk-news/value-tools-not-in-the-insurer-toolkit-yet/60%Monthly2018-01-17 19:41
https://realendpoints.com/mk-news/drug-pricing-with-value-debate-in-full-swing-icers-influence-grows/60%Monthly2018-01-22 15:27
https://realendpoints.com/mk-news/can-slow-selling-heart-drug-entresto-perk-up-in-2017-novarits-hopes-so/60%Monthly2018-02-05 21:21
https://realendpoints.com/mk-news/lawyers-drugs-and-money/60%Monthly2018-01-17 19:09
https://realendpoints.com/mk-news/big-pharmas-offer-to-trump-discounts-when-drugs-dont-work/60%Monthly2018-01-17 19:09
https://realendpoints.com/mk-news/multiple-sclerosis-patients-see-drug-value-differently-than-payers-and-doctors/60%Monthly2018-01-17 19:07
https://realendpoints.com/mk-news/what-to-look-out-for-at-acc/60%Monthly2018-02-05 21:22
https://realendpoints.com/mk-news/cancer-progress-and-the-budgetary-wolf/60%Monthly2018-01-21 18:36
https://realendpoints.com/mk-news/is-amgens-fourier-enough-for-physicians-payers-to-expand-repatha-use/60%Monthly2018-02-05 21:23
https://realendpoints.com/mk-news/amgen-sinks-as-cvot-results-draw-mixed-payer-reactions/60%Monthly2018-01-21 18:34
https://realendpoints.com/mk-news/will-physician-demand-for-repatha-put-pressure-on-payer-restrictions/60%Monthly2018-02-05 21:18
https://realendpoints.com/mk-news/risky-business/60%Monthly2018-01-21 18:45
https://realendpoints.com/mk-news/to-get-pricing-right-pharma-must-understand-payer-behavior-trump-or-no-trump/60%Monthly2018-01-17 18:35
https://realendpoints.com/mk-news/drugmakers-try-new-strategy-amid-price-criticism-charging-less/60%Monthly2018-01-17 18:11
https://realendpoints.com/mk-news/enbrels-first-outcomes-contract-is-with-harvard-pilgrim-others-may-follow/60%Monthly2018-02-05 21:17
https://realendpoints.com/mk-news/wac-a-mol/60%Monthly2018-01-17 18:08
https://realendpoints.com/mk-news/can-cholesterol-drug-sponsors-make-the-case-for-statin-intolerance/60%Monthly2018-02-05 21:23
https://realendpoints.com/mk-news/few-clouds-on-high-priced-ultra-orphan-drug-horizon/60%Monthly2018-02-05 21:24
https://realendpoints.com/mk-news/entresto-facing-pressure-from-diabetes-drugs/60%Monthly2018-02-05 21:25
https://realendpoints.com/mk-news/novartiss-entresto-voyage-hindsight-is-20-20/60%Monthly2018-02-05 21:25
https://realendpoints.com/mk-news/why-drugmakers-arent-sweating-the-next-wave-of-patent-losses/60%Monthly2018-01-17 18:01
https://realendpoints.com/mk-news/proving-the-value-of-value-based-deals/60%Monthly2018-01-17 18:00